Novavax is a US-based biotechnology company focused solely on the development of innovative vaccines to solve the world’s most pressing infectious disease challenges. Since our founding in 1987, we have been committed to developing novel products that leverage our innovative proprietary recombinant nanoparticle vaccine technology to help prevent a broad range of infectious diseases. Our proprietary recombinant nanoparticle technology platform has the potential to produce highly immunogenic antigens. We produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Novavax scientists bring years of integrity, study, and experience to the development of new and promising vaccines.
©Novavax, Inc. (2021) 08/21 COM-US-COV-2100008
AAP Nat Con